Literature DB >> 27073619

Moieties in antidiabetic drugs as a target of insulin receptors in association with common neurological disorders.

David Calderón Guzmán1, Hugo Juárez Olguín2, Ernestina Hernández García2, Maribel Ortiz Herrera3, Norma Osnaya Brizuela1.   

Abstract

Insulin is a peptide that can be harmful with regards to neuroplasticity, neuroprotection and neuromodulation. Furthermore, the role of insulin highlights its relevance in the progress of diverse clinical disorders as well as in the mechanisms associated with certain pathogenesis and their evolution towards diabetes, obesity and neurodegenerative diseases. The precise molecular mechanisms by which these diseases are induced remain to be elucidated. The benefits in knowing/discovering these mechanisms in animal models and humans cannot be undermined. An in depth understanding of the principal risk factors leading to obesity and their management is vital in the implementation of early-life strategies of intervention and prevention, with a view to avoid adverse late-life outcomes. Therefore, the aim of the present study was to review their possible association with antidiabetic drugs.

Entities:  

Keywords:  antidiabetic drugs; central nervous system; insulin; neurodegenerative disorders; obesity

Year:  2016        PMID: 27073619      PMCID: PMC4812541          DOI: 10.3892/br.2016.616

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  44 in total

1.  Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-κB activation: Use of insulin to attenuate metformin's effect.

Authors:  Pasquale Picone; Domenico Nuzzo; Luca Caruana; Elisa Messina; Annalisa Barera; Sonya Vasto; Marta Di Carlo
Journal:  Biochim Biophys Acta       Date:  2015-02-07

Review 2.  Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.

Authors:  Maka S Hedrington; Stephen N Davis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-02-02       Impact factor: 4.481

3.  Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease.

Authors:  J K Morris; H Zhang; A A Gupte; G L Bomhoff; J A Stanford; P C Geiger
Journal:  Brain Res       Date:  2008-09-11       Impact factor: 3.252

Review 4.  The use of insulin detemir during pregnancy: a safety evaluation.

Authors:  Ronit Koren; Yoel Toledano; Moshe Hod
Journal:  Expert Opin Drug Saf       Date:  2015-03-02       Impact factor: 4.250

5.  Inhaled insulin--a new delivery for an old drug.

Authors:  Heidi Collins Fantasia
Journal:  Nurs Womens Health       Date:  2015 Feb-Mar

Review 6.  Metformin and metabolic diseases: a focus on hepatic aspects.

Authors:  Juan Zheng; Shih-Lung Woo; Xiang Hu; Rachel Botchlett; Lulu Chen; Yuqing Huo; Chaodong Wu
Journal:  Front Med       Date:  2015-02-12       Impact factor: 4.592

7.  An increase in glucose concentration in the lateral ventricles of the brain induces changes in autonomic nervous system activity.

Authors:  R L Camargo; R Torrezan; J C de Oliveira; R C S Branco; L F Barella; S Grassiolli; C Gravena; P C F Mathias
Journal:  Neurol Res       Date:  2013-01       Impact factor: 2.448

8.  Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders?

Authors:  M Hallschmid; B Schultes
Journal:  Diabetologia       Date:  2009-08-25       Impact factor: 10.122

Review 9.  CNS insulin signaling in the control of energy homeostasis and glucose metabolism - from embryo to old age.

Authors:  Merly C Vogt; Jens C Brüning
Journal:  Trends Endocrinol Metab       Date:  2012-12-19       Impact factor: 12.015

Review 10.  Oxidative stress, glutamate, and neurodegenerative disorders.

Authors:  J T Coyle; P Puttfarcken
Journal:  Science       Date:  1993-10-29       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.